Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab

Mullin K.; Kudrow D.; Croop R.; Lovegren M.; Coric V; Conway C. M.; Lipton R. B.

首页> 外文期刊>Headache >Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab

【24h】

Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab

机译：口腔CGRP受体拮抗剂和单克隆抗体组合中的急性治疗中受益于：RMegepant 75mg用于埃伦亚姆预防治疗期间的攻击症

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Headache》 |2019年第1期|共2页
作者
Mullin K.; Kudrow D.; Croop R.; Lovegren M.; Coric V; Conway C. M.; Lipton R. B.;
展开▼
作者单位

New England Inst Neurol &

Headache Stamford CT USA;

Calif Med Clin Headache Santa Monica CA USA;

Biohaven Pharmaceut New Haven CT USA;

Biohaven Pharmaceut New Haven CT USA;

Biohaven Pharmaceut New Haven CT USA;

Biohaven Pharmaceut New Haven CT USA;

Albert Einstein Coll Med Bronx NY 10467 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献
专利

1. Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab [J] . Mullin K., Kudrow D., Croop R., Headache . 2019,第Suppla1期

机译：口腔CGRP受体拮抗剂和单克隆抗体组合中的急性治疗中受益于：RMegepant 75mg用于埃伦亚姆预防治疗期间的攻击症
2. Efficacy, Safety, and Tolerability of Rimegepant 75 Mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-blind, Randomized, Placebo-controlled Trial, Study 301 [J] . Lipton R. B., Conway C. M., Stock E. G., Headache . 2018,第8期

机译：术语急性治疗偏头部的急性治疗效果，安全性和耐受性75mg的疗效，安全性和耐受性：双盲，随机，安慰剂对照试验的结果301
3. Efficacy, Safety, and Tolerability of Rimegepant 75 Mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-blind, Randomized, Placebo-controlled Trial, Study 302 [J] . Lipton R. B., Coric V, Stock E. G., Headache . 2018,第8期

机译：初始治疗的疗效，安全性和耐受性，口服CGRP受体拮抗剂，用于偏头痛的急性治疗：双盲，随机，安慰剂对照试验，研究302
4. Laser magnetic therapy for acute epididymitis and acute apididymo-orchitis treatment [C] . Moufagued Maati, Russian State Medical Univ., Moscow, Laser Methods for Biomedical Applications: ALT '96 International Symposium . 1996

机译：激光磁疗治疗急性附睾炎和急性附睾睾丸炎
5. Cloning and expression of a biosimilar chimeric monoclonal antibody directed against the human epidermal growth factor receptor and its production in CHO cells for treatment of colo-rectal cancer. [D] . Motiwala, Hatim Maqbulhusen. 2012

机译：针对人表皮生长因子受体的生物仿制药嵌合单克隆抗体的克隆和表达及其在CHO细胞中的产生，用于治疗结肠直肠癌。
6. A novel therapeutic concept for the treatment of acute angioedema attacks in hereditary angioedema patients: multiple successful treatments even in severe swelling attacks with the bradykinin-B2 receptor antagonist Icatibant [O] . M Bas, J Greve, G Kojda, 2006

机译：一种用于治疗遗传性血管性水肿患者的急性血管性水肿发作的新颖治疗概念：使用缓激肽-B2受体拮抗剂依卡替班即使在严重的肿胀发作中也能获得多种成功的治疗方法
7. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy [O] . 2020

机译：小分子CGRP受体拮抗剂加上单克隆抗体在偏头痛治疗中的潜力

Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab

著录项

相似文献

相关主题

期刊订阅